dc.contributor.author |
Yüksel, Doğangün |
|
dc.contributor.author |
Ilgan, S. |
|
dc.contributor.author |
Arslan, N. |
|
dc.contributor.author |
Ugur, O. |
|
dc.contributor.author |
Oztürk, E. |
|
dc.contributor.author |
Bayhan, H. |
|
dc.date.accessioned |
2019-08-16T11:49:03Z |
|
dc.date.available |
2019-08-16T11:49:03Z |
|
dc.date.issued |
2000 |
|
dc.identifier.issn |
0363-9762 |
|
dc.identifier.uri |
https://hdl.handle.net/11499/5540 |
|
dc.identifier.uri |
https://doi.org/10.1097/00003072-200003000-00008 |
|
dc.description.abstract |
Purpose: This study evaluated the biodistribution of Tc-99m (V) DMSA in patients with superscans on bone imaging and defined its role in differentiating the underlying cause. Methods: Nine patients (five with metastatic and four with metabolic bone disease) with classical superscans were entered into the study. All patients had the necessary radiologic and biochemical studies and a final diagnosis was reached accordingly. Tc-99m (V) DMSA scintigraphy was performed 1 week after Tc-99m MDP whole-body bone imaging. Results: In four of five patients with widespread skeletal metastases, Tc-99m (V) DMSA scan showed diffusely increased bone uptake. In the remaining patient, the Tc-99m (V) DMSA scan showed a normal distribution pattern. All patients with metabolic bone disease had increased bone uptake on Tc-99m (V) DMSA scans. Conclusion: Tc-99m (V) DMSA shows increased bone uptake in patients having a superscan appearance in metastatic or metabolic bone disease. Tc-99m (V) DMSA imaging may play a role in the evaluation of patients with equivocal bone scan findings for a superscan. |
en_US |
dc.language.iso |
en |
en_US |
dc.relation.ispartof |
Clinical Nuclear Medicine |
en_US |
dc.rights |
info:eu-repo/semantics/closedAccess |
en_US |
dc.subject |
Classical bone scan |
en_US |
dc.subject |
Pentavalent Tc-99m DMSA |
en_US |
dc.subject |
Superscan |
en_US |
dc.subject |
Tc-99m MDP |
en_US |
dc.subject |
medronate technetium tc 99m |
en_US |
dc.subject |
succimer tc 99m |
en_US |
dc.subject |
adult |
en_US |
dc.subject |
aged |
en_US |
dc.subject |
article |
en_US |
dc.subject |
biochemistry |
en_US |
dc.subject |
bone metastasis |
en_US |
dc.subject |
bone scintiscanning |
en_US |
dc.subject |
clinical article |
en_US |
dc.subject |
controlled study |
en_US |
dc.subject |
drug distribution |
en_US |
dc.subject |
drug uptake |
en_US |
dc.subject |
female |
en_US |
dc.subject |
human |
en_US |
dc.subject |
male |
en_US |
dc.subject |
metabolic bone disease |
en_US |
dc.subject |
radiodiagnosis |
en_US |
dc.subject |
Adult |
en_US |
dc.subject |
Aged |
en_US |
dc.subject |
Bone and Bones |
en_US |
dc.subject |
Bone Diseases, Metabolic |
en_US |
dc.subject |
Bone Neoplasms |
en_US |
dc.subject |
Female |
en_US |
dc.subject |
Humans |
en_US |
dc.subject |
Male |
en_US |
dc.subject |
Middle Aged |
en_US |
dc.subject |
Radiopharmaceuticals |
en_US |
dc.subject |
Technetium Tc 99m Dimercaptosuccinic Acid |
en_US |
dc.title |
The role of Tc-99m (V) DMSA scintigraphy in the evaluation of superscan on bone scintigraphy |
en_US |
dc.type |
Article |
en_US |
dc.identifier.volume |
25 |
en_US |
dc.identifier.issue |
3 |
en_US |
dc.identifier.startpage |
193 |
|
dc.identifier.startpage |
193 |
en_US |
dc.identifier.endpage |
196 |
en_US |
dc.authorid |
0000-0003-0983-2834 |
|
dc.identifier.doi |
10.1097/00003072-200003000-00008 |
|
dc.relation.publicationcategory |
Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı |
en_US |
dc.identifier.pmid |
10698416 |
en_US |
dc.identifier.scopus |
2-s2.0-0343920705 |
en_US |
dc.identifier.wos |
WOS:000085434300008 |
en_US |